98%
921
2 minutes
20
Introduction: The COVID-19 patients in the convalescent stage noticeably have pulmonary diffusing capacity impairment (PDCI). The pulmonary diffusing capacity is a frequently-used indicator of the COVID-19 survivors' prognosis of pulmonary function, but the current studies focusing on prediction of the pulmonary diffusing capacity of these people are limited. The aim of this study was to develop and validate a machine learning (ML) model for predicting PDCI in the COVID-19 patients using routinely available clinical data, thus assisting the clinical diagnosis.
Methods: Collected from a follow-up study from August to September 2021 of 221 hospitalized survivors of COVID-19 18 months after discharge from Wuhan, including the demographic characteristics and clinical examination, the data in this study were randomly separated into a training (80%) data set and a validation (20%) data set. Six popular machine learning models were developed to predict the pulmonary diffusing capacity of patients infected with COVID-19 in the recovery stage. The performance indicators of the model included area under the curve (AUC), Accuracy, Recall, Precision, Positive Predictive Value(PPV), Negative Predictive Value (NPV) and F1. The model with the optimum performance was defined as the optimal model, which was further employed in the interpretability analysis. The MAHAKIL method was utilized to balance the data and optimize the balance of sample distribution, while the RFECV method for feature selection was utilized to select combined features more favorable to machine learning.
Results: A total of 221 COVID-19 survivors were recruited in this study after discharge from hospitals in Wuhan. Of these participants, 117 (52.94%) were female, with a median age of 58.2 years (standard deviation (SD) = 12). After feature selection, 31 of the 37 clinical factors were finally selected for use in constructing the model. Among the six tested ML models, the best performance was accomplished in the XGBoost model, with an AUC of 0.755 and an accuracy of 78.01% after experimental verification. The SHAPELY Additive explanations (SHAP) summary analysis exhibited that hemoglobin (Hb), maximal voluntary ventilation (MVV), severity of illness, platelet (PLT), Uric Acid (UA) and blood urea nitrogen (BUN) were the top six most important factors affecting the XGBoost model decision-making.
Conclusion: The XGBoost model reported here showed a good prognostic prediction ability for PDCI of COVID-19 survivors during the recovery period. Among the interpretation methods based on the importance of SHAP values, Hb and MVV contributed the most to the prediction of PDCI outcomes of COVID-19 survivors in the recovery period.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10466769 | PMC |
http://dx.doi.org/10.1186/s12911-023-02192-6 | DOI Listing |
JTCVS Open
August 2025
Division of Cardiothoracic Surgery, Children's Hospital of Philadelphia, Philadelphia, Pa.
[This corrects the article DOI: 10.1016/j.xjon.
View Article and Find Full Text PDFCureus
August 2025
Division of Thoracic and Cardiovascular Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata, JPN.
Cerebral infarction is a rare but serious complication after pulmonary resection for lung cancer. A 78-year-old man with hypertension and diabetes underwent video-assisted thoracoscopic right middle lobectomy for stage IA2 adenocarcinoma. On postoperative day 1, he developed acute right hemiparesis and motor aphasia.
View Article and Find Full Text PDFNat Med
September 2025
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Immune checkpoint blockade (ICB) is standard of care in advanced diffuse pleural mesothelioma (DPM), but its role in the perioperative management of DPM is unclear. In tandem, circulating tumor DNA (ctDNA) ultra-sensitive residual disease detection has shown promise in providing a molecular readout of ICB efficacy across resectable cancers. This phase 2 trial investigated neoadjuvant nivolumab and nivolumab/ipilimumab in resectable DPM along with tumor-informed liquid biopsy residual disease assessments.
View Article and Find Full Text PDFAm J Respir Crit Care Med
September 2025
Aalborg University Hospital, Anaesthesia and Intensive Care, Aalborg, North Denmark Region, Denmark.
Rationale: In intensive care unit (ICU) patients lower oxygenation targets may impair long-term cognitive function, while higher targets may impair long-term pulmonary function.
Objectives: To assess the effects of a partial pressure of arterial oxygen (PaO) target of 60 vs 90 mmHg on one-year cognitive and pulmonary functions in ICU survivors of acute hypoxemic respiratory failure.
Methods: 3654 patients were randomized in the Handling Oxygenation Targets in the ICU and the Handling Oxygenation Targets in COVID-19 trials: 1916 (52.
Radiol Med
September 2025
Breast Imaging Division, Radiology Department, IEO European Institute of Oncology IRCCS, 20141, Milan, Italy.
Metastatic involvement (MB) of the breast from extramammary malignancies is rare, with an incidence of 0.09-1.3% of all breast malignancies.
View Article and Find Full Text PDF